ATE326985T1 - Lyophilisierte pharmazeutische zusammensetzung von propofol - Google Patents

Lyophilisierte pharmazeutische zusammensetzung von propofol

Info

Publication number
ATE326985T1
ATE326985T1 AT03702813T AT03702813T ATE326985T1 AT E326985 T1 ATE326985 T1 AT E326985T1 AT 03702813 T AT03702813 T AT 03702813T AT 03702813 T AT03702813 T AT 03702813T AT E326985 T1 ATE326985 T1 AT E326985T1
Authority
AT
Austria
Prior art keywords
propofol
pharmaceutical composition
lyophilized pharmaceutical
relates
composition
Prior art date
Application number
AT03702813T
Other languages
German (de)
English (en)
Inventor
Lawrence John Penkler
Barry Paul Daisley
Original Assignee
Shimoda Biotech Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shimoda Biotech Pty Ltd filed Critical Shimoda Biotech Pty Ltd
Application granted granted Critical
Publication of ATE326985T1 publication Critical patent/ATE326985T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03702813T 2002-02-01 2003-01-29 Lyophilisierte pharmazeutische zusammensetzung von propofol ATE326985T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA200200929 2002-02-01
US40163302P 2002-08-06 2002-08-06

Publications (1)

Publication Number Publication Date
ATE326985T1 true ATE326985T1 (de) 2006-06-15

Family

ID=27669352

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03702813T ATE326985T1 (de) 2002-02-01 2003-01-29 Lyophilisierte pharmazeutische zusammensetzung von propofol

Country Status (12)

Country Link
US (1) US20050239746A1 (https=)
EP (1) EP1469886B8 (https=)
JP (1) JP2005522422A (https=)
CN (1) CN1625414A (https=)
AT (1) ATE326985T1 (https=)
AU (1) AU2003205930B2 (https=)
BR (1) BR0307518A (https=)
CA (1) CA2474710A1 (https=)
DE (1) DE60305438T2 (https=)
MX (1) MXPA04007328A (https=)
NZ (1) NZ534598A (https=)
WO (1) WO2003063824A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1574221T3 (da) * 2004-03-10 2007-07-16 Shimoda Biotech Pty Ltd Stabile, injicérbare diclofenacsammensætninger
US20060198891A1 (en) 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
KR20080003860A (ko) 2005-04-13 2008-01-08 가부시키가이샤 오츠까 세이야꾸 고죠 프로포폴 함유 지방 유제
CN101287447B (zh) * 2005-08-12 2012-10-24 印度血清及疫苗有限公司 包含丙泊酚的水性麻醉剂组合物
US8580954B2 (en) 2006-03-28 2013-11-12 Hospira, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
EP2106786A1 (de) 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin
DK2484350T3 (en) * 2011-02-04 2016-08-01 Norbert Univ -Prof Dr Med Roewer A pharmaceutical composition containing a complex of a cyclodextrin with a propofolsalt
ES2784629T3 (es) 2011-11-29 2020-09-29 Jurox Pty Ltd Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona
CN103172658B (zh) * 2011-12-26 2016-01-20 宜昌人福药业有限责任公司 一种适合药用的前体药物晶型、制备方法及药用组合物
WO2014075935A1 (de) 2012-11-15 2014-05-22 Sapiotec Gmbh Delphinidinkomplex als antiphlogistischer oder immunsuppressiver wirkstoff
US9949947B2 (en) 2012-12-11 2018-04-24 Sapiotec Gmbh Delphinidin for combating melanoma cells
EP2913050A1 (de) * 2014-02-28 2015-09-02 SapioTec GmbH Verfahren zur Herstellung eines Flurankomplexes
CN104523591B (zh) * 2014-12-19 2019-01-18 西安力邦肇新生物科技有限公司 无致敏性、无痛丙泊酚脂肪微乳冻干制剂配方和制备方法
CN111529695A (zh) * 2020-04-30 2020-08-14 首都医科大学附属北京康复医院(北京工人疗养院) 一种环糊精可溶性ace2及其制备方法和应用
KR20220057901A (ko) * 2020-10-30 2022-05-09 현대자동차주식회사 차아염소산수를 이용한 차량용 살균장치 및 그 제어방법
FR3117337B1 (fr) 2020-12-10 2023-04-28 Centre Hospitalier Univ De Lille Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable
CN118715017A (zh) * 2022-02-18 2024-09-27 贝伦治疗公益公司 用2-羟基丙基-β-环糊精治疗高甘油三酯血症

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA828580B (en) * 1981-12-23 1983-10-26 Schering Corp Interferon formulations
ZA962214B (en) * 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition
AU5774796A (en) * 1995-06-13 1997-01-09 Dyer, Alison Margaret Pharmaceutical compositions containing lornoxicam and cyclod extrin
ATE238072T1 (de) * 1996-02-19 2003-05-15 Amersham Health As Verbesserungen an (oder im bezug auf) kontrastmittel
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6440414B1 (en) * 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
ATE285770T1 (de) * 1999-10-29 2005-01-15 Merck & Co Inc Verfahren zur herstellung von carbapenem- antibiotika zubereitungen
IN187686B (https=) * 2000-06-21 2002-06-08 Bharat Serums & Vaccines Ltd
JP4334229B2 (ja) * 2001-03-20 2009-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤

Also Published As

Publication number Publication date
DE60305438D1 (de) 2006-06-29
CN1625414A (zh) 2005-06-08
EP1469886B8 (en) 2008-01-09
CA2474710A1 (en) 2003-08-07
NZ534598A (en) 2004-11-26
WO2003063824A2 (en) 2003-08-07
WO2003063824A3 (en) 2004-06-17
EP1469886A2 (en) 2004-10-27
US20050239746A1 (en) 2005-10-27
MXPA04007328A (es) 2005-07-05
BR0307518A (pt) 2004-12-28
JP2005522422A (ja) 2005-07-28
AU2003205930B2 (en) 2007-08-16
EP1469886B1 (en) 2006-05-24
DE60305438T2 (de) 2006-12-21

Similar Documents

Publication Publication Date Title
ATE326985T1 (de) Lyophilisierte pharmazeutische zusammensetzung von propofol
AU9163701A (en) Topical composition containing at least one vitamin D or one vitamin D analogue and at least one corticosteroid
DK1187928T3 (da) Viruslignende partikler, fremstilling og anvendelse ved screening samt ved funktionel genomics
BR0113663A (pt) Composições de pelìcula de pectina
FR2841900B1 (fr) Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
ATE445386T1 (de) Polymerische parfümpartikel
ATE250431T1 (de) Verbesserte zusammensetzungen mit unkomplexiertem cyclodextrin zur geruchskontrolle
SG170087A1 (en) Pharmaceutical compositions
NO20035301D0 (no) Små molekyl¶re antagonister av proteiner i BCL-2-familien
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
CY1118180T1 (el) Μεθοδος για παρασκευη στερεας φαρμακευτικης συνθεσης
EP1505990A4 (en) METHOD FOR THE TREATMENT OF HEPATITIS
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
BR0308486A (pt) Composição tópica compreendendo um ciclofrutano, um veìculo e uma droga
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
DE60143363D1 (de) Pharmazeutische zusammensetzungen, die die immunogenität von schwach immunogenen antigenen fördern
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
DE69924304D1 (de) N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin
ATE333901T1 (de) Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
EA200100674A1 (ru) Клатраты дегидроэпиандростерона и соответствующие фармацевтические композиции
EA200501301A1 (ru) Ментоловые растворы лекарственных препаратов
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
AR048672A1 (es) Tabletas de desintegracion que comprenden licarbazepina
EA200702496A1 (ru) Местная композиция, содержащая желатин

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties